The U.S. Federal Trade Commission is seeking additional information from Bristol-Myers Squibb Co and Celgene Corp. The focus of their investigation is on the companies’ psoriasis treatments as part of its review of their planned merger, Bristol-Myers said.
“The parties understand that the FTC’s review is focused on marketed and pipeline products for the treatment of psoriasis,” Bristol-Myers said in a filing. Celgene’s psoriasis drug Otezla brought $448 million in sales in the quarter ended Dec. 31.